创新药如何不再“用药难”

Core Viewpoint - The article discusses the challenges and recent supportive measures for the application of innovative drugs, particularly CAR-T and ADC therapies, highlighting the issues of high costs and accessibility for patients [1]. Group 1: Pricing of Innovative Drugs - The high cost of innovative drugs, such as CAR-T priced at 1.29 million yuan per injection, poses a significant burden on patients [2]. - To reduce R&D costs, policies have been introduced to streamline clinical trial approvals, aiming for a 30-day review period for certain innovative drugs [2]. - The integration of AI and big data in drug development is being promoted to enhance efficiency and lower costs [2]. Group 2: Accessibility in Hospitals - Patients have reported difficulties in accessing innovative drugs even when they are covered by insurance, due to various considerations by medical institutions [4]. - Measures have been proposed to facilitate the entry of innovative drugs into designated medical institutions, addressing the complexity of their administration [4]. - The establishment of a trading platform for innovative drugs is suggested to improve accessibility for patients [4]. Group 3: Sustainable Development of Innovative Drugs - Some innovative drugs are conditionally approved, requiring further clinical trials post-approval to validate their safety and efficacy [5]. - There is a need for real-world evidence to support the clinical use of innovative drugs, which will enhance public confidence and regulatory oversight [6]. - The collaboration between the National Medical Insurance Administration and the National Health Commission aims to promote the evaluation of innovative drugs' effectiveness in real-world settings [6].